28 results
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
may conclude that a financial relationship between Tenet and a principal investigator has created a conflict of interest or otherwise affected
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
are not involved in any situation that might create, or appear to create, a conflict of interest with respect to your loyalty or duties to the Company
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
relationship between Tenet and a principal investigator has created a conflict of interest or otherwise affected
interpretation of the clinical trial
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authorities may therefore
DEFA14A
33wcmbago8
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
3231koch
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
10-K
dycizlkmj19ioaz8d7iw
7 Mar 22
Annual report
4:03pm
10-Q
mrdyo4cc fzg
13 Sep 21
Quarterly report
4:01pm
424B4
0liagr3bwhtz lts
11 Aug 21
Prospectus supplement with pricing info
5:05pm